Kindred Biosciences (KIN) Tops Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Kindred Biosciences Announces Third Quarter 2016 Financial Results
November 7, 2016 9:01 AM ESTSAN FRANCISCO, Nov. 7, 2016 /PRNewswire/ --Â Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the third quarter ended September 30, 2016 and provided updates on its programs.
"We are pleased with the progress across our programs as we execute our strategy of quickly and cost-effectively developing therapeutics for our animal family members. In support of the anticipated launch of Zimeta (dipyrone injection) and Mirataz (mirtazapine 2% ointment), we have been hiring key... More
